Pharmacy Benefit Management

From Specialty Pharmacy News - Although the FDA has yet to approve a product through the 351(k) biosimilar pathway, multiple follow-on drugs are working their way through the pipeline, noted Kate Keeping, senior director of biosimilars research for BioTrends Research Group at a June 30 webinar sponsored by the company. “The United States is the only developed market to have no biosimilars, but development is ramping up,” Keeping said. As of June, 23 biosimilar products were in U.S. Read more

From Drug Benefit News - Marking another key step in the long-awaited arrival of biosimilars to the U.S., Sandoz on July 24 said the FDA accepted biosimilar filgrastim for review. Sandoz, a Novartis Group company, is the first firm to announce a biosimilar filing under the pathway created in the Biologics Price Competition and Innovation Act contained in the health reform law. Read more

Pharmacy Benefit Management Blog

By Lauren Flynn Kelly - August 21, 2014
Earlier this month, CVS Caremark Corp. and Express Scripts Holding Co. released updates to their 2015 formulary exclusion lists. CVS Caremark now excludes nearly 100 products from its Standard Formulary and automatically will leave out new-to-market products, including line extensions and new...
By Lauren Flynn Kelly - August 7, 2014
During recent conference calls to discuss the publicly traded PBMs’ second-quarter 2014 earnings, there was less talk of the role narrow and/or preferred pharmacy networks are playing in the 2015 selling season than there has been in recent years. Consultants say that nearly all the PBMs now...
By Angela Maas - July 31, 2014
Could a larger movement against specialty drugs placed on high formulary tiers be spurred by the actions of consumer advocacy groups in California and Florida against health plans and their coverage of HIV/AIDS drugs and requirements for members who take them? Consumer Watchdog and The AIDS...

It's quick and easy to sign up for FREE access to!

Why do I need to register?